for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Halozyme Therapeutics, Inc.

HALO.O

Latest Trade

40.23USD

Change

-0.91(-2.21%)

Volume

786,570

Today's Range

39.55

 - 

41.40

52 Week Range

12.71

 - 

41.55

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
41.14
Open
41.16
Volume
786,570
3M AVG Volume
39.59
Today's High
41.40
Today's Low
39.55
52 Week High
41.55
52 Week Low
12.71
Shares Out (MIL)
135.18
Market Cap (MIL)
5,438.41
Forward P/E
43.94
Dividend (Yield %)
--

Next Event

Halozyme Therapeutics Inc at Piper Sandler Healthcare Conference (Virtual)

Latest Developments

More

Halozyme Raises Full Year 2020 Guidance

Horizon Therapeutics PLC And Halozyme Therapeutics Inc Enter Global Collaboration And License Agreement For Enhanze Technology

Halozyme Announces CHMP Recommends EU Approval Of Roche's Phesgo For Her2-Positive Breast Cancer

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Halozyme Therapeutics, Inc.

Halozyme Therapeutics, Inc. is a biotechnology company focused on developing and commercializing oncology therapies. The Company operates in research, development and commercialization of human enzymes and other drug candidates. The Company's segment also includes research and development activities and product sales of Hylenex recombinant. The Company's development pipeline consists of clinical-stage product candidates in oncology. Its lead oncology program is PEGPH20 (polyethylene glycol (PEG)ylated recombinant human hyaluronidase), a molecular entity being developed for the systemic treatment of tumors, which accumulate HA. It is in Phase II and Phase III clinical testing for PEGPH20 in stage IV pancreatic ductal adenocarcinoma (Studies 109-202 and 109-301); Phase Ib clinical testing in non-small cell lung cancer (Study 107-201), and in Phase Ib clinical testing in non-small cell lung cancer and gastric cancer (Study 107-101).

Industry

Biotechnology & Drugs

Contact Info

11388 Sorrento Valley Rd

SAN DIEGO, CA

92121-1345

United States

+1.858.7948889

https://www.halozyme.com/

Executive Leadership

Connie L. Matsui

Independent Chairman of the Board

Helen I. Torley

President, Chief Executive Officer, Director

Elaine D. Sun

Chief Financial Officer, Senior Vice President

Jean-Pierre Bizzari

Independent Director

Bernadette M. Connaughton

Independent Director

Key Stats

2.27 mean rating - 11 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2017

0.3K

2018

0.2K

2019

0.2K

2020(E)

0.3K
EPS (USD)

2017

0.450

2018

-0.560

2019

-0.500

2020(E)

0.856
Price To Earnings (TTM)
262.29
Price To Sales (TTM)
27.25
Price To Book (MRQ)
55.02
Price To Cash Flow (TTM)
216.96
Total Debt To Equity (MRQ)
397.66
LT Debt To Equity (MRQ)
397.66
Return on Investment (TTM)
5.67
Return on Equity (TTM)
4.81

Latest News

Latest News

Genmab shares drop on legal battle with J&J over cancer drug

Shares in Danish biotech firm Genmab <GMAB.CO> fell as much as 14% on Wednesday after it said it was locked in a legal battle with its partner Johnson & Johnson <JNJ.N> over royalty payments for its key cancer drug.

BRIEF-Halozyme To Receive $10 Million Milestone Payment From Janssen

* HALOZYME TO RECEIVE $10 MILLION MILESTONE PAYMENT FROM JANSSEN

BRIEF-Halozyme To Receive $15 Mln Milestone Payment From Janssen

* HALOZYME TO RECEIVE $15 MILLION MILESTONE PAYMENT FROM JANSSEN

BRIEF-Halozyme Reports Q1 Loss Per Share $0.04

* Q1 EARNINGS PER SHARE ESTIMATE $-0.02 -- REFINITIV IBES DATA

BRIEF-Janssen Submits NDA In Japan For Daratumumab Subcutaneous Formulation Utilizing Halozyme's Enhanze Tech For Patients With Multiple Myeloma

* JANSSEN SUBMITS NDA IN JAPAN FOR DARATUMUMAB SUBCUTANEOUS FORMULATION UTILIZING HALOZYME'S ENHANZE TECH FOR PATIENTS WITH MULTIPLE MYELOMA Source text for Eikon: Further company coverage:

BRIEF-Artisan Partners Limited Partnership Reports 10.5% Passive Stake In Halozyme Therapeutics

* ARTISAN PARTNERS LIMITED PARTNERSHIP REPORTS 10.5% PASSIVE STAKE IN HALOZYME THERAPEUTICS INC AS OF MARCH 31- SEC FILING Source text : (https://bit.ly/34pGO5F) Further company coverage:

BRIEF-Halozyme Says FDA Accepted BLA For Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Enhanze® Technology

* HALOZYME ANNOUNCES FDA HAS ACCEPTED BIOLOGICS LICENSE APPLICATION FOR FIXED-DOSE SUBCUTANEOUS COMBINATION OF PERJETA® AND HERCEPTIN® USING ENHANZE® TECHNOLOGY

BRIEF-Halozyme licenses new enhanze targets for $25 million upfront payment, future milestones and royalties

* HALOZYME LICENSES NEW ENHANZE TARGETS FOR $25 MILLION UPFRONT PAYMENT, FUTURE MILESTONES AND ROYALTIES

BRIEF-Halozyme Therapeutics Says CEO Helen Torley's 2017 Compensation Was $5.18 Mln

* HALOZYME THERAPEUTICS INC SAYS CEO HELEN I. TORLEY'S 2017 TOTAL COMPENSATION WAS $5.18 MILLION VERSUS $4.85 MILLION IN 2016 – SEC FILING Source text - https://bit.ly/2udFEM8 Further company coverage:

BRIEF-Halozyme Reports Q4 Earnings Per Share $0.85

* REITERATED 2018 FINANCIAL GUIDANCE FOR NET REVENUE OF $115 MILLION TO $125 MILLION Source text for Eikon: Further company coverage:

BRIEF-Halozyme Projects 25 To 30 Percent Enhanze Royalty Growth In 2018

* HALOZYME PROJECTS 25 TO 30 PERCENT ENHANZE ROYALTY GROWTH IN 2018

BRIEF-Alexion And Halozyme Enter License Agreement For ENHANZE Technology

* ALEXION AND HALOZYME ENTER LICENSE AGREEMENT FOR ENHANZE TECHNOLOGY Source text for Eikon: Further company coverage:

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up